Speaker illustration

Doctor Daniel Gaudet

ECOGENE-21 and Community gene medicine center, clinical lipidology unit, Montreal (Canada)

Member of:

European Society of Cardiology

Dr. Gaudet is a lipidologist and professor of Medicine at the Université de Montréal (UdeM). He has been and is still principal investigator of several academic studies or clinical trials (PoC and phase 1 to 3) in clinical lipidology. Over the years, he has collaborated to several expert consensus on rare or severe lipid disorders including those of the World Health Organization on FH, the European Atherosclerosis Society and recently those of the National Lipid Association and the American Society of Preventive Cardiology on severe hypertriglyceridemia. He founded and leads ECOGENE-21, a non-profit research organization dedicated to access to innovation for unmet medical needs. Dr. Gaudet is the author of more than 400 scientific publications in peer-reviewed journals and several books and book chapters.

Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results

Event: ESC Congress 2024

Topic: Drug therapy

Session: Secondary prevention: a multifactorial approach

Thumbnail

Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia

Event: ESC Congress 2024

Topic: Drug therapy

Session: Lipid-lowering therapies: new findings

Thumbnail

ANGPTL3 antisense oligonucleotide to lower triglycerides

Event: ESC Congress 2020

Topic: Drug therapy

Session: Late-Breaking Science in Lipids

Thumbnail